Genmab — Oktober 2022
-
AbbVie Inc. (ABBV) Q3 2022 Earnings Call Transcript
https://seekingalpha.com/article/4550412-abbvie-inc-abbv-q3-2022-earnings-call-transcript -
I et bear-marked, hvor der raser recession på de økonomiske globale markeder, er det vigtig, man som investor har polstret sine porteføljer med aktier, som er både stresstestet og trykprøvet i deres evne til ikke at falde dybt ned, når der kommer negative nyheder. Og hvilke sektorer og aktier mener jeg, det er godt at være i? Det kan du høre om i denne video. https://www.proinvestor.com/boards/107378
-
Highlight Abbvie Earnings Call "We're seeking accelerated approval based on the positive Phase 2 study results for epcoritamab in this indication where we saw very deep and durable responses in these highly refractory patients. We expect decisions in both U.S. and Europe in 2023."
-
Se ugens mange regnskaber: https://www.proinvestor.com/finanskalender
-
'While AbbVie does face several near-term pressures, we believe the firm is making strides with its pipeline, but probably needs to augment internal efforts with increased acquisitions. Within the pipeline, we are bullish on recently filed lymphoma drug epcoritamab.' https://www.morningstar.com/articles/1121828/abbvie-posts-solid-q3-earnings-but-uncertain-outlook-for-humira-likely-weighing-on-stock
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind